BR112022020706A2 - Anticorpos contra sars-cov-2 e métodos de uso dos mesmos - Google Patents

Anticorpos contra sars-cov-2 e métodos de uso dos mesmos

Info

Publication number
BR112022020706A2
BR112022020706A2 BR112022020706A BR112022020706A BR112022020706A2 BR 112022020706 A2 BR112022020706 A2 BR 112022020706A2 BR 112022020706 A BR112022020706 A BR 112022020706A BR 112022020706 A BR112022020706 A BR 112022020706A BR 112022020706 A2 BR112022020706 A2 BR 112022020706A2
Authority
BR
Brazil
Prior art keywords
cov
sars
antigen
infection
methods
Prior art date
Application number
BR112022020706A
Other languages
English (en)
Inventor
Corti Davide
Fink Katja
Beltramello Martina
Cameroni Elisabetta
Pinto Dora
Bianchi Siro
Samuele Pizzuto Matteo
Zatta Fabrizia
Snell Gyorgy
Czudnochowski Nadine
Telenti Amalio
A Lempp Florian
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of BR112022020706A2 publication Critical patent/BR112022020706A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS CONTRA SARS-COV-2 E MÉTODOS DE USO DOS MESMOS. A presente revelação provê anticorpos e fragmentos de ligação a antígeno dos mesmos que podem se ligar a um antígeno de SARS-CoV-2 e, em determinadas modalidades, têm capacidade de neutralizar uma infecção de SARS-CoV-2. Em determinadas modalidades, os anticorpos atualmente revelados têm capacidade de se ligar a proteínas S de múltiplos sarbecovírus e/ou neutralizar infecção por múltiplos sarbecovírus. São também providos polinucleotídeos que codificam um anticorpo ou fragmento de ligação a antígeno, vetores e células hospedeiras que compreendem um polinucleotídeo, composições farmacêuticas, e métodos de uso dos anticorpos atualmente revelados, fragmentos de ligação a antígeno, polinucleotídeos, vetores, células hospedeiras, e composições para tratar ou diagnosticar uma infecção por sarbecovírus, tais como uma infecção de SARS-CoV-2.
BR112022020706A 2020-04-14 2021-04-14 Anticorpos contra sars-cov-2 e métodos de uso dos mesmos BR112022020706A2 (pt)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US202063010025P 2020-04-14 2020-04-14
US202063015399P 2020-04-24 2020-04-24
US202063019926P 2020-05-04 2020-05-04
US202063021063P 2020-05-06 2020-05-06
US202063023808P 2020-05-12 2020-05-12
US202063030254P 2020-05-26 2020-05-26
US202063036631P 2020-06-09 2020-06-09
US202063046452P 2020-06-30 2020-06-30
US202063057557P 2020-07-28 2020-07-28
US202063091841P 2020-10-14 2020-10-14
US202163166879P 2021-03-26 2021-03-26
US202163170360P 2021-04-02 2021-04-02
US202163171892P 2021-04-07 2021-04-07
PCT/US2021/027375 WO2021211775A1 (en) 2020-04-14 2021-04-14 Antibodies against sars-cov-2 and methods of using the same

Publications (1)

Publication Number Publication Date
BR112022020706A2 true BR112022020706A2 (pt) 2022-11-29

Family

ID=75787315

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020706A BR112022020706A2 (pt) 2020-04-14 2021-04-14 Anticorpos contra sars-cov-2 e métodos de uso dos mesmos

Country Status (7)

Country Link
US (1) US20240059757A1 (pt)
EP (1) EP4135846A1 (pt)
JP (1) JP2023523549A (pt)
CN (1) CN116194476A (pt)
BR (1) BR112022020706A2 (pt)
CA (1) CA3175533A1 (pt)
WO (1) WO2021211775A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3872091T3 (da) * 2020-02-26 2023-09-11 Vir Biotechnology Inc Antistoffer mod sars-cov-2
AU2021306709A1 (en) 2020-07-06 2023-02-09 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting SARS-CoV-2
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting Sars-cov-2
WO2023102476A1 (en) * 2021-12-02 2023-06-08 California Institute Of Technology Antibodies for coronaviruses and uses thereof
WO2023143176A1 (zh) * 2022-01-28 2023-08-03 山东博安生物技术股份有限公司 SARS-CoV-2病毒的广谱抗体及其应用
WO2023201256A1 (en) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023215910A1 (en) 2022-05-06 2023-11-09 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
WO2024086566A2 (en) * 2022-10-19 2024-04-25 The Board Of Trustees Of The Leland Stanford Junior University Pan-sarbecovirus neutralizing antibodies and methods of use thereof
WO2024102674A1 (en) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
CN106459182B (zh) 2013-12-30 2021-09-03 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途
JP6587696B2 (ja) 2015-05-13 2019-10-09 ズムトール バイオロジクス、インコーポレイテッド アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
MX2020003145A (es) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos.

Also Published As

Publication number Publication date
US20240059757A1 (en) 2024-02-22
EP4135846A1 (en) 2023-02-22
JP2023523549A (ja) 2023-06-06
WO2021211775A1 (en) 2021-10-21
CA3175533A1 (en) 2021-10-21
CN116194476A (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
BR112022015374A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
BR112022017048A2 (pt) Anticorpos contra sars-cov-2 e métodos para usar os mesmos
MX2022013886A (es) Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).
BR112016016699A2 (pt) Anticorpos humanos para pd-1
BR112019012040A2 (pt) anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73.
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112017003194A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra.
BR112019008634A2 (pt) anticorpos anti-pd-l1 e variantes
BR112022001460A2 (pt) Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
BR112023005684A2 (pt) Anticorpos contra sars-cov-2
BR112015030892A2 (pt) Proteína de ligação ao antígeno, anticorpo monoclonal, ácido nucleico recombinante, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma proteína de ligação ao antígeno ou anticorpo humanizado, e, método para produzir uma proteína de ligação ao antígeno
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
BR112017014771A2 (pt) ?anticorpo, polinucleotídeo, unidade de expressão, célula hospedeira, métodos para produção de um anticorpo e para tratamento de um indivíduo, composição, uso de um anticorpo em um método de diagnóstico, e, vetor de expressão?
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
WO2019165122A8 (en) Neutralizing antibodies to hiv-1 env and their use
BR112021009275A2 (pt) Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.
BRPI0708101B1 (pt) anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
BR112021016272A2 (pt) Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
BR112022012474A2 (pt) Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes.
BR112017001782A2 (pt) fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing